A SURVEY ON THE USE OF VASOPRESSOR AND INOTROPIC AGENTS OVER
THREE MONTHS AT THE KENYATTA NATIONAL HOSPITAL

DISSERTATION SUBMITTED IN PART FULFILMENT OF THE REQUIREMENTS FOR
THE DEGREE OF MASTER OF MEDICINE IN ANAESTHESIA OF THE UNIVERSITY
OF NAIROBI

Principal investigator:

Simiyu Victoria M., MBChB (UoN)
DECLARATION

Principal investigator:

I hereby declare that this dissertation is my original work and that it has not been submitted to any university or institution for examination or any other purposes.

Signed ____________________________ Date ________________

Simiyu V.M., MBChB (UoN)

Post-graduate student in Anaesthesia

University of Nairobi registration number: H58/68385/2011

Supervisors:

This dissertation has been submitted for the degree of masters of medicine in anaesthesiology with my approval as a university supervisor.

Signed ____________________________ Date ________________

Dr. J.M. Muriithi,

MBChB, MMed Anaesthesia (UoN)

Lecturer in Anaesthesiology; Department of Anaesthesia, UoN.

Signed ____________________________ Date ________________

Dr. S. Nabulindo,

MBChB, MMed Anaesthesia (UoN)

Lecturer in Anaesthesiology; Department of Anaesthesia UoN.
# TABLE OF CONTENTS

DECLARATION ................................................................................................................................. 2  
TABLE OF CONTENTS ..................................................................................................................... 3  
ABSTRACT ........................................................................................................................................ 4  
LIST OF ABBREVIATIONS ............................................................................................................... 7  
OPERATIONAL DEFINITIONS ........................................................................................................ 8  
LIST OF TABLES ............................................................................................................................. 8  
INTRODUCTION ............................................................................................................................. 10  
LITERATURE REVIEW .................................................................................................................... 11  
STUDY OBJECTIVES ....................................................................................................................... 20  
STUDY JUSTIFICATION .................................................................................................................. 21  
RESEARCH METHODOLOGY .......................................................................................................... 22  
  Study design .................................................................................................................................. 22  
  Study population and size .............................................................................................................. 22  
  Sampling procedure ....................................................................................................................... 23  
  Data collection procedure, management and analysis ................................................................. 24  
  Data analysis plan .......................................................................................................................... 25  
  Ethical considerations .................................................................................................................. 28  
RESULTS .......................................................................................................................................... 30  
DISCUSSION .................................................................................................................................... 41  
CONCLUSIONS ............................................................................................................................... 46  
RECOMMENDATIONS ..................................................................................................................... 47  
Appendix 1: Consent for participation in study ............................................................................. 48  
Appendix 2: Study Data Form ......................................................................................................... 53  
Appendix 3: Approval letter ............................................................................................................ 58  
REFERENCES .................................................................................................................................... 59
ABSTRACT

Background

In Kenyatta National Hospital vasopressor and inotropic agents are used in specialized units-CCU and HDU. Knowledge of the varied pharmacology and mechanism of action of the agents allows for proper selection and thus desired outcome. This is done by medical staff with appropriate experience and training. These drugs are known to impact on patient outcome though guidelines are not readily available to give guidance on management and allow for standardization of treatment. Therefore individual experience and preference determines selection.

Objective

To survey the use of vasopressor and inotropic agents over three months at KNH.

Study design

An observational, descriptive study.

Setting

Kenyatta National Hospital-Critical care unit, emergency ward, high dependency units. It was carried out over three months from approval of the study.

Study population
Patients admitted in the above units on inotrope or vasopressor agent that was initiated at KNH.

Sample size

The sample size was determined by the modified Fisher’s formula:

=70

Sampling procedure

Convenient sampling was used to select the patients. The eligible patients were recruited consecutively into the study using the inclusion criteria

Inclusion criteria;

- Patients in main CCU and Emergency ward on inotropic/vasopressor agent initiated at KNH.
- Patients who gave consent to participate in the study.

Exclusion criteria;

- Patients who didn't consent to participate in the study.
- Patients transferred to KNH who were already on inotropic or vasopressor therapy.

Study variables

These included identifying the types of inotropic/vasopressor agents available, document their indications, modes of haemodynamic monitoring and the techniques used to administer the agents.
Data management and analysis

Data was presented as numbers (%) or mean ± SD and summarized using tables, histograms and pie-charts as appropriate. Descriptive and inferential statistics were used to analyze the data.

All analyses were performed using SPSS (statistical package for the social sciences) Statistics (version 20, Chicago, IL).

Results

Data from 70 patients were collected and recorded. 94% were adult patients. 59% of the patients were female. The leading cause for initiating inotropes was septic shock (48.6%). The inotropes that are available for use were dopamine, norepinephrine, epinephrine and dobutamine in order of most prescribed agent. In patients with septic shock norepinephrine and dopamine were the inotropes of choice while in cardiogenic shock epinephrine and dobutamine were the inotropes of choice. 97% of the time inotropes were initiated on the same day. The mode of haemodynamic monitoring commonly used is basic monitoring (defined in this study as heart rate, pulse oximeter, central venous pressure and non-invasive blood pressure). Through the study quick change was used in substituting inotrope infusion. Infusion pumps were used to administer the agents 100% of the time.

Conclusion

The use of inotropes/vasopressors at the Kenyatta National Hospital is fairly well executed in the critical care areas.
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
</tr>
<tr>
<td>AHA</td>
<td>American heart association</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary artery bypass graft</td>
</tr>
<tr>
<td>CCU</td>
<td>Critical Care Unit</td>
</tr>
<tr>
<td>CO</td>
<td>Cardiac output</td>
</tr>
<tr>
<td>CVP</td>
<td>Central venous pressure</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiograph</td>
</tr>
<tr>
<td>HDU</td>
<td>High dependency Unit</td>
</tr>
<tr>
<td>KNH</td>
<td>Kenyatta National Hospital</td>
</tr>
<tr>
<td>MAP</td>
<td>Mean Arterial Pressure</td>
</tr>
<tr>
<td>SHO</td>
<td>Senior House Officer</td>
</tr>
<tr>
<td>SOAP</td>
<td>Sepsis occurrence in the acutely ill patients</td>
</tr>
<tr>
<td>SV</td>
<td>Stroke volume</td>
</tr>
<tr>
<td>SVR</td>
<td>Systemic vascular resistance</td>
</tr>
<tr>
<td>UCI</td>
<td>University of California Irvine</td>
</tr>
</tbody>
</table>
OPERATIONAL DEFINITIONS

Basic monitoring refers to minimal expected monitoring. This includes ECG, non-invasive BP, heart rate, central venous pressure.

Advanced monitoring refers to superior modes of monitoring that can be in addition to the basic monitoring. Invasive BP in an example.

LIST OF TABLES

Table 1: Table showing receptor physiology ..............................................................13
Table 2: Table showing clinical application of inotropes/vasopressors......................14
Table 3: Number of inotropes/vasopressor used in septic shock.................................32
Table 4: Inotrope choice in cardiogenic shock..............................................................33
Table 5: Number of inotropes post open heart surgery...............................................33
Table 6: Inotropes used on paediatric patients............................................................34
Table 7: Type of shock in those with pre-treatment MAP <40mmHg............................35
Table 8: Type of shock among patients that were fluid resuscitated............................36
Table 9: Patients not fluid resuscitated..........................................................................37

LIST OF FIGURES

Figure 1: Figure showing the relative vasopressor activity of the common inotropes and vasopressor agents.................................................................13
Figure 2: A graph showing the age distribution of patients included in the study.........30
Figure 3: The inotropes in use.................................................................31
Figure 4: The indication for initiating inotropes...........................................31
Figure 5: Choice of inotrope in the septic shock group.................................32
Figure 6: Admitting diagnosis........................................................................34
Figure 7: Pre-treatment circulatory state...........................................................35
Figure 8: Type of fluid used for resuscitation....................................................37
Figure 9: Time of inotrope initiation from time of prescription..........................38
Figure 10: first inotrope of choice...................................................................39
Figure 11: second inotrope of choice.................................................................39
Figure 12: Mean arterial pressure set target ......................................................40
Figure 13: achievement of target.....................................................................40
Figure 14: Mode of monitoring treatment..........................................................41
INTRODUCTION

The Kenyatta National Hospital is a referral hospital and the teaching hospital of the University of Nairobi. The hospital receives many patients who in the course of their treatment require inotropes and vasopressor agents. These agents are known to be life saving when initiated in good time and appropriately thus improving outcome, morbidity and mortality.

Vasopressors are class of drugs that elevate Mean Arterial Pressure (MAP) by inducing vasoconstriction while inotropes increase cardiac contractility. These drugs have both vasopressor and inotropic effects.

Vasopressors are indicated for a decrease of >30 mmHg from baseline systolic blood pressure or MAP <60 mmHg, when either condition results in end-organ dysfunction secondary to hypoperfusion. In the paediatric age group MAP varies with age. Therefore need of inotropes will be based on individual patients and clinical presentation.

They are highly potent drugs that should be administered by medical staff with appropriate experience and training. These drugs are usually administered by anaesthesia practitioners who also manage the critically ill patients in KNH. This may be in operating theatres or in a critical care unit set-up. They may also be called upon to give advice on the use of these agents in the medical wards and high dependency units.

The anaesthesia practitioners who also manage critically ill patients in KNH include:

- Anaesthesiologists
• Anaesthesiologists in training (SHO)

Intensivists are clinicians who may also prescribe inotropes. An intensivist is a physician who specializes in the care and management of patients in the intensive care. They from different medical specialities. In KNH the intensivists include internal medicine physicians, paediatricians and anaesthesiologists.

The critically ill patients at the KNH are found in the following units: critical care unit, emergency ward in casualty, high dependency units-cardiac and neurosurgery. This study is aimed at assessing the use of inotropic and vasopressor agents in the mentioned areas and be able to describe the agents available, indications and the monitoring that is used, through an observational study with a questionnaire as the data collection tool. A similar study has not been carried out at KNH.

LITERATURE REVIEW

Historical background

Dopamine was released in 1974 for use as an inotrope. Dopamine is one of the most complex and often misunderstood inotropic agents. The pharmacodynamic and haemodynamic effects are based on the dose administered. At low doses dopamine enhances perfusion of vital organs and at higher doses is a vasopressor (1).

Dobutamine is a synthetic analog of dopamine. It was released in 1978 and was designed to be a selective inotropic agent based on Ahlmquist's theories of adrenergic stimulation. It was later found to have peripheral vascular activity (1).
Extracts of the adrenal gland date as far back as 1895 discovered by Napoleon Cybulski while Japanese chemist Jokichi Takamine and his assistant Keizo Uenaka independently discovered adrenaline in 1900. Four years later it was synthesized in the laboratory by Friedrich Stolz and Henry Drysdale Dakin (2).

Use of inotropic and vasopressor agents in the management of patients with shock has increased. They are generally administered to improve cardiac output (CO) or vascular tone that has been severely compromised by often life-threatening clinical conditions. These agents are indicated for a decrease of >30 mmHg from baseline systolic blood pressure or MAP <60 mmHg when either result in end organ dysfunction due to hypoperfusion (3).

**Receptor physiology**

The categories of adrenergic receptors relevant to vasopressor activity are alpha-1 adrenergic receptor, beta-1, beta-2 adrenergic receptors and dopamine receptors. Actions of these drugs on receptors influence the cardiac output and mean arterial pressure. Cardiac output is the product of heart rate and stroke volume while mean arterial pressure is the product of cardiac output and peripheral resistance.

Terms that are commonly used in describing the drug effects are inotropy, chronotropy and vasoconstriction. Inotropy refers to drugs that alter the force of cardiac muscle contraction while chronotropy drugs that cause change of the heart rate by affecting the nerves controlling the heart or by changing the rhythm produced by the sino-atrial node. Vasoconstriction is the narrowing of the blood vessels resulting from contraction of the muscular wall to decrease in the caliber of the blood vessel.
The relative vasopressor activity of the common inotropes and vasopressor agents is dependent on receptor activity as summarized by figure 1 and table 1.

**Alpha Activity**

\[ \text{norepinephrine} = \text{epinephrine} > \text{dopamine} > \text{phenylephrine} \]

**Beta Activity**

\[ \text{epinephrine} > \text{dopamine} > \text{norepinephrine} \]

Figure 1

<table>
<thead>
<tr>
<th>Receptor Physiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptor</td>
</tr>
<tr>
<td><strong>Alpha-1 Adrenergic</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Beta Adrenergic</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Dopamine</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>subtype</strong></td>
</tr>
</tbody>
</table>

Table 1
REVIEW OF THE PHARMACOLOGY AND INDICATIONS OF THE AGENTS

Inotropes are used to manipulate critically ill patients’ physiology, to maintain tissue perfusion and prevent end organ damage. At the point where patients are adequately resuscitated yet remain hypotensive the initiation of vasopressors may be required to achieve the desired MAP. Selection of a vasopressor is determined by the cause of shock and the desired therapeutic activity targeting the underlying pathogenesis. This is summarized on table 2.

<table>
<thead>
<tr>
<th>Clinical Application</th>
<th>1st Line Agent</th>
<th>2nd Line Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septic Shock</td>
<td>Norepinephrine</td>
<td>Vasopressin</td>
</tr>
<tr>
<td></td>
<td>Dopamine</td>
<td>Epinephrine</td>
</tr>
<tr>
<td>Heart Failure</td>
<td>Dopamine</td>
<td>Milrinone</td>
</tr>
<tr>
<td></td>
<td>Dobutamine</td>
<td></td>
</tr>
<tr>
<td>Cardiogenic Shock</td>
<td>Norepinephrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dobutamine</td>
<td></td>
</tr>
<tr>
<td>Anaphylactic Shock</td>
<td>Epinephrine</td>
<td>Vasopressin</td>
</tr>
<tr>
<td>Neurogenic Shock</td>
<td>Phenylephrine</td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>Anesthesia-induced Phenylephrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Following CABG Epinephrine</td>
<td></td>
</tr>
</tbody>
</table>

Table 2

SEPTIC SHOCK

Currently norepinephrine and dopamine are the first line vasopressors in septic shock management (4). A comparison study by SOAP II showed no significant difference between mortality rate between patients with shock on dopamine as first line or norepinephrine;
dopamine was found to have more adverse events (5). Epinephrine should be the next alternative in septic shock resistant to norepinephrine or dopamine. Martin et al did a study identifying factors associated with outcome in septic shock. Norepinephrine was found to be strongly related to favourable outcome resulting in decreased mortality (6).

**Dopamine**

At low doses (0.5 to 3 μg · kg
\(^{-1}\) · min
\(^{-1}\)), stimulation of dopaminergic D\(_1\) receptors and D\(_2\) receptors present in the vasculature and renal tissues promotes vasodilation and increased blood flow to these tissues. At intermediate doses (3 to 10 μg · kg
\(^{-1}\) · min
\(^{-1}\)), dopamine weakly binds to β\(_1\)-adrenergic receptors, promoting norepinephrine release and inhibiting reuptake in presynaptic sympathetic nerve terminals, which results in increased cardiac contractility and chronotropy, with a mild increase in SVR. At higher infusion rates (10 to 20 μg · kg
\(^{-1}\) · min
\(^{-1}\)), α\(_1\)-adrenergic receptor–mediated vasoconstriction dominates.

**Norepinephrine**

Norepinephrine is a potent α\(_1\)-adrenergic receptor agonist with modest β-agonist activity, which renders it a powerful vasoconstrictor with less potent direct inotropic properties. This agent has minimal chronotropic effects, which makes it attractive for use in settings in which heart rate stimulation may be undesirable.

**Vasopressin**

It exerts its circulatory effects through V\(_1\) (V\(_{1a}\) in vascular smooth muscle, V\(_{1b}\) in the pituitary gland) and V\(_2\) receptors (renal collecting duct system). V\(_{1a}\) stimulation mediates constriction of vascular smooth muscle.
A vasopressin-modulated increase in vascular sensitivity to norepinephrine augments its pressor effects. The pressor effects of vasopressin are relatively preserved during hypoxic and acidotic conditions, which commonly develop during shock of any origin. Evidence suggests that low dose (<0.04U/min) is safe and effective for the treatment of vasodilatory shock (7).

**Epinephrine**

Epinephrine has high affinity for β₁-, β₂-, and α₁-receptors present in cardiac and vascular smooth muscle. β-Adrenergic effects are more pronounced at low doses (1-4 mcg/min) and α₁-adrenergic effects at higher doses (>10mcg/min).

**CARDIOGENIC SHOCK**

The ACC/AHA guidelines for ST-elevation myocardial infarction (STEMI) recommend the selection of vasopressor and/or inotrope therapy based on SBP plus the presence or absence of signs and symptoms of shock (8). For patients with a SBP of 70-100 mmHg, dobutamine is recommended in the absence of shock and dopamine if shock is present. Norepinephrine is recommended when SBP is < 70 mmHg (8).

In a French multi centre survey the commonest used inotropes were dobutamine (65%) , norepinephrine (31%) and epinephrine (24%) in the management of low cardiac output syndrome (LCOS) (9).

In Germany in the management of LCOS epinephrine (41.8%) was found to be the commonest. Followed by dobutamine (30.9%) and phosphodiesterase inhibitors (14.8%) (10).
**Dobutamine**

Dobutamine has a strong affinity for both β₁- and β₂-receptors (3:1 ratio). At lower doses (≤5 µg · kg⁻¹ · min⁻¹) causes mild vasodilation while at high doses up to 15 µg · kg⁻¹ · min⁻¹ increases cardiac contractility without greatly affecting peripheral resistance. Vasoconstriction dominates at higher infusion rates.

Dobutamine increases myocardial oxygen consumption. This property is applied in diagnostic perfusion imaging; but conversely, limits its use in clinical conditions in which induction of ischemia is potentially harmful. Ventricular arrhythmias are not dose dependant and tolerance develops within days of therapy (11).

**Norepinephrine**

Increases diastolic pressure that inturn improves coronary flow. The coronary flow is further improved by local vasodilators from the myocytes. Prolonged use has direct toxic effects on myocytes.

**Epinephrine**

Improves coronary blood flow by increased duration of diastole and release of local vasodilators. High doses and prolonged use damages arterial walls.

**NEUROGENIC SHOCK**

In acute spinal cord injury patients may present in neurogenic shock. Studies have shown improved neurological outcome associated with aggressive management and maintenance of a target MAP of 85-90mmHg.
**Phenylephrine**

It’s the preferred vasopressor in neurogenic shock and hypotension as it has potent $\alpha$-adrenergic activity and no affinity for $\beta$-adrenergic receptors. It’s used as a rapid bolus to correct sudden severe hypotension.

**HYPOVOLAEMIC SHOCK**

Haemorrhage progressing to haemorrhagic shock, is the leading cause of preventable death in trauma (12). There is no well-defined mean arterial pressure (MAP) goal for patients with hemorrhagic shock. Early initiation of vasopressor within 24hrs in poorly resuscitated patients has been associated with increased mortality (13). The mainstay of therapy is damage control resuscitation, which focuses on a massive transfusion of equal ratios of packed red blood cells to fresh frozen plasma to platelets plus surgical intervention (14).

Generally, inotropes have been shown to improve post-operative morbidity and mortality (15). This was achieved through balancing the beneficial effects of increased cardiac output against increased myocardial oxygen demand with inotrope use.

A practice survey on vasopressor and inotropic drug therapy in Scandinavian intensive care units concluded that dopamine (47%) and noradrenaline (40%) were the most
commonly used agents. Indications for inotropic/vasopressor use were hypotension (92%) and oliguria (50%). 32% used more than one drug (16).

In a French multicentre survey on the use of inotropes after cardiac surgery it was found that a single inotrope was used in 64% of cases, two inotropes in 26%, and three in 6%. Dobutamine was administered to 334 patients (65%). norepinephrine was the second most commonly chosen inotrope (157 patients [31%]), followed by epinephrine (24%) (17).

**ADMINISTRATION AND MONITORING**

Basic hemodynamic monitoring that is required while on inotropes/vasopressors includes continuous ECG and BP monitoring. This is because these drugs have a short half life and overdoses can be life threatening. Central venous pressure and central venous saturation are additional parameters that should be monitored. In paediatrics central venous saturation may be used, with a target aim of >70% (18). It should be administered by nursing and medical staff with appropriate experience and training. Preparation and checking of calculations, dosages and dilutions should be done by two members of staff. This ensures mistakes are avoided.

Most agents must be administered through a central vein, although dobutamine is generally well tolerated via a peripheral vein. The 2002 guidelines on paediatric and neonatal septic shock recommended not giving cardiovascular agents until central vascular access was attained. This was because there was and still is concern that administration of peripheral vasoactive agents (especially vasopressors) could result in peripheral vascular/tissue injury. However, after implementation of the 2002 guidelines, the literature showed that, depending on availability of skilled personnel, it could take two
ormore hours to establish central access. Because mortality went up with delay in time to inotrope drug use, the 2007 update now recommends use of peripheral inotropes (not vasopressors) until central access is attained (19). Continuous controlled infusions with horizontal syringes are used to administer the inotrope/vasopressor.

Error in labelling is a recognised risk in the safe administration of injectable medicines. All areas of the label should be completed. Place the label so that text is upright and ensure that the burette graduations are not obscured. The date and time that the line is required to be changed must be identified. The line should be labeled twice.

There are two methods of substituting the infusion of inotropes through intravenous pump quick change (QC) and double pumping (DP). Quick change is whereby the empty syringe is changed as fast as possible with a ready filled syringe while double pumping uses two pumps at the same time to ensure no break in the infusion of the agents. Quick change was the quickest and most cost-effective (20). Infusions expire after 24 hr and when changing ensure infusion line is clamped as the syringe is loaded into the driver, as the agent may be administered during the process.
STUDY OBJECTIVES

GENERAL OBJECTIVE

To assess the practice of inotropic and vasopressor therapy in the critically ill patients at KNH.

SPECIFIC OBJECTIVES

1. To identify the types of inotropic and vasopressor agents available.
2. To document indications of use of the inotropic and vasopressor therapy.
3. To evaluate modes of haemodynamic monitoring.
4. To assess the technique of administration of inotropic and vasopressor therapy.
STUDY JUSTIFICATION

This research was intended to assess the use of inotropes and vasopressor agents at KNH. Inotropic/vasopressor agents are regularly used at the Kenyatta National Hospital though data to show the extent and pattern of use is not available. This is because such a study has not yet been done. These vasoactive agents are lifesaving and highly potent as they cause minute by minute change. This study will allow KNH to have data on the common indications of these agents and to be aware of the commonest used agents. This allows for planning and appropriate stocking of the hospital units that often use these agents.

There are currently no guidelines available on the use of inotropes and vasopressors. This study will assist in the formation of guidelines that will be pivotal in improving patient care in the referral hospital. Guidelines allow for standardization of care that greatly improves quality of care.
RESEARCH METHODOLOGY

Study Design

A prospective -observational study.

Study Site

The study was conducted at the Kenyatta National Hospital main Critical Care Unit and the Emergency ward and the High Dependency units.

Study population

Patients admitted in KNH main CCU, High Dependency Units and Emergency ward initiated on inotropic/vasopressor agents.

Sample size

The sample size was determined by the formula:

\[ n = \frac{t^2 \times p(1-p)}{m^2} \]

Description:

- \( n \) = required sample size
- \( t \) = the standard normal deviation at the required confidence level (in this case 1.96)
- \( p \) = is the proportion in the target population estimated to have characteristics being measured. Since there is no estimate available of the proportion in the target population assumed to have the characteristics of interest, 50 % (0.5) as recommended by Fisher et al
Thus, \( n = 1.96 \times 1.96 \times 0.5(1 - 0.5) \times 0.05 \times 0.05 \)

\[ n = 384 \]

since the study population in this study was less than 10000, the sample size was calculated as follows:

\[ n_f = \frac{n}{1 + \frac{n}{N}} \]

\( n_f \) = the desired sample size (when the population is less than 10,000)

\( n \) = the desired sample size (when the population is more than 10,000) which is 384 (as calculated above)

\( N \) = the estimate of the population size (estimated number of patients on inotropic/vasopressor therapy in KNH in a year)

Thus

\[ N_f = \frac{384}{1 + (384/96)} \]

\[ = 70 \]

**Sampling procedure**
The study population was obtained from KNH-CCU, HDU and Emergency ward patients who were initiated on inotropic support. Convenient sampling was used to select the patients. The eligible patients were recruited consecutively into the study using the inclusion criteria below.

**Inclusion criteria;**

- Patients in main CCU and Emergency ward initiated on inotropic/vasopressor agent.
- Patients who consented to participate in the study.

**Exclusion criteria;**

- Patients who did not consent to participate in the study.
- Patients transferred to KNH who were already on inotropic or vasopressor therapy.

**Data collection procedure**

The eligible patients or their next of kin for those unable to give consent were required to give informed consent and complete a consent form before being involved in the study. The consenting process involved explaining to the patients or their next of kin the aim of the study, confidentiality and the use of the results. This was by the primary investigator. This took approximately ten minutes to ensure the patient or the next of kin had understood the content of the informed consent form. The presence of a witness (the primary nurse) was to ensure that the consenting procedure was done well and no relevant information was withheld. The primary nurse was the nurse allocated to care for the patient. The consent was administered at the point at which the decision to initiate inotropes was made. One copy of the consent was placed in the patients file and one copy retained by the primary investigator. The
consent copy with the investigator will be retained for a maximum of seven years. The data was collected using a questionnaire which was filled by the investigator. The information was from the medical records.

The investigator may have needed to interview the primary clinician in the unit to clarify but not to add to the information from the medical records. This was for the purposes of data quality control. The primary clinician was the SHO covering the floor at the mentioned study areas involved in the day to day patient care. Once data had been collected from the patient's file a yellow sticker was put on the cover of every file to avoid double recruitment.

Data Management and analysis

Data was presented as numbers (%) or mean ± SD and summarized using tables, histograms and pie-charts as appropriate. Descriptive and inferential statistics was used to analyze the data.

All analyses were performed using SPSS (statistical package for the social sciences) Statistics (version 20, Chicago, IL).

Data analysis plan

DUMMY TABLES

TABLE 1: socio-demographic characteristics

<table>
<thead>
<tr>
<th>variable</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(yrs)</td>
<td></td>
</tr>
</tbody>
</table>

26
<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
</table>

**TABLE 2: indications for vasopressor/inotropic agent**

<table>
<thead>
<tr>
<th>variable</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septic shock</td>
<td></td>
</tr>
<tr>
<td>Cardiogenic shock</td>
<td></td>
</tr>
<tr>
<td>Anaphylactic shock</td>
<td></td>
</tr>
<tr>
<td>Neurogenic shock</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 3: Inotrope/vasopressor choice**

<table>
<thead>
<tr>
<th>Drug</th>
<th>1&lt;sup&gt;st&lt;/sup&gt;</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt;</th>
<th>3&lt;sup&gt;rd&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dopamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopreterenol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenylephrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vasopressin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 4: Number of inotropes used**

<table>
<thead>
<tr>
<th>Number of inotropes used</th>
<th>Frequencies (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 5: mode of monitoring**

<table>
<thead>
<tr>
<th>Mode of monitoring</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td></td>
</tr>
<tr>
<td>advanced</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 6: Mode of administration

<table>
<thead>
<tr>
<th>Mode</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infusion pump</td>
<td></td>
</tr>
<tr>
<td>other</td>
<td></td>
</tr>
</tbody>
</table>

Ethical considerations

During the study the following ethical issues were considered:

1. No names of patients or practitioners were used in this study.

2. The study had no harmful effects on subjects. No extra costs were incurred by study subjects.

3. Treatment was not withheld from those who declined to participate in the study.

4. Permission to conduct the study was sought from the Kenyatta National Hospital/University of Nairobi – Ethics & Research Committee prior to commencement.

5. Study findings will be shared with the ethics body as well as University of Nairobi, to facilitate appropriate policy formulation aimed at improving patient care.

6. Deficits found were discussed with the primary team and appropriate action was taken.
RESULTS

This was a survey on the use of vasopressor and inotropic agents over three months at the Kenyatta National Hospital. A total of 70 patients were recruited into the study. Of these 29 were male and 41 were female. Majority of the patients were between 25 and 35 years. The mean age was 34.6yrs.

Figure 2: A graph showing the age distribution of patients included in the study
Through the study period four inotropes were available. Dopamine was most prescribed followed by norepinephrine.

**Figure 3: The inotropes in use**

Indications of inotropes were grouped into the different types of shock; septic, cardiogenic and neurogenic shock.

**Figure 4: The indication for initiating inotropes**
In the septic shock group the inotropes of choice were dopamine and norepinephrine. There were 35 patients with septic shock. Of these 18 were on single inotrope while 17 were on double inotrope in the course of management as noted on table 3 below.

Figure 5: Choice of inotrope in the septic shock group

Table 3: Number of inotropes/vasopressor used in septic shock

<table>
<thead>
<tr>
<th>Septic Shock</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single Inotrope</td>
<td>18</td>
<td>51.4</td>
</tr>
<tr>
<td>Double Inotropes</td>
<td>17</td>
<td>48.6</td>
</tr>
</tbody>
</table>
There were 32 patients with cardiogenic shock. 23 were post open heart surgery. The inotropes on choice were dobutamine, dopamine and epinephrine as presented on table 4 below.

**Table 4: inotrope choice in cardiogenic shock**

<table>
<thead>
<tr>
<th>Inotrope</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>dobutamine</td>
<td>9</td>
<td>28.1</td>
</tr>
<tr>
<td>dopamine</td>
<td>9</td>
<td>28.1</td>
</tr>
<tr>
<td>epinephrine</td>
<td>14</td>
<td>43.8</td>
</tr>
</tbody>
</table>

The patients post open heart surgery were either on single or double inotropes in the course of management as presented on table 5 below.

**Table 5: Number of inotropes post open heart surgery**

<table>
<thead>
<tr>
<th>Heart Surgery</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single Inotrope</td>
<td>20</td>
<td>87.0</td>
</tr>
<tr>
<td>Double Inotrope</td>
<td>3</td>
<td>13.0</td>
</tr>
</tbody>
</table>
Inotrope choice in paediatric patients in the study presented on table 6 below.

**Table 6: inotropes used on paediatric patients**

<table>
<thead>
<tr>
<th>Inotrope</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine</td>
<td>2</td>
<td>50</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>2</td>
<td>50</td>
</tr>
</tbody>
</table>

Patients had various admitting diagnosis in the different critical care areas. Majority of the patients were post open heart surgery and sepsis

**Figure 6: Admitting diagnosis**

![Admitting diagnosis chart](image-url)
Pre-treatment circulatory state of the patients was based on mean arterial pressure. Majority of the patients had a mean arterial pressure of between 40-60mmHg.

**Figure 7: Pre-treatment circulatory state**

In the group of patients with MAP of < 40mmHg majority had septic shock as shown on table 7 below.

**Table 7: Type of shock in those with pre-treatment MAP <40mmHg**

<table>
<thead>
<tr>
<th>Pressure &lt;40</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septic shock</td>
<td>19</td>
<td>90.5</td>
</tr>
<tr>
<td>Cardiogenic</td>
<td>2</td>
<td>9.5</td>
</tr>
</tbody>
</table>
Fluid resuscitation in response to the hypotension was done on 39 patients while 31 of the patients were not fluid resuscitated. Majority of the patients who were fluid resuscitated had septic shock as shown on table 8 below.

**Table 8: Type of shock among patients that were fluid resuscitated**

<table>
<thead>
<tr>
<th>Type of shock</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiogenic Shock</td>
<td>2</td>
<td>5.1</td>
</tr>
<tr>
<td>Neurogenic Shock</td>
<td>3</td>
<td>7.7</td>
</tr>
<tr>
<td>Septic Shock</td>
<td>34</td>
<td>87.2</td>
</tr>
</tbody>
</table>
Patients were either resuscitated with crystalloids or blood as shown by the pie chart below.

**Figure 8: Type of fluid used for resuscitation**

<table>
<thead>
<tr>
<th>Blood</th>
<th>Crystalloid</th>
</tr>
</thead>
<tbody>
<tr>
<td>8%</td>
<td>92%</td>
</tr>
</tbody>
</table>

In the group of patients who were not fluid resuscitated most of the patients had cardiogenic shock.

**Table 9: Patients who were not fluid resuscitated**

<table>
<thead>
<tr>
<th>Type of shock</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiogenic Shock</td>
<td>30</td>
<td>93.8</td>
</tr>
<tr>
<td>Septic Shock</td>
<td>2</td>
<td>6.2</td>
</tr>
</tbody>
</table>
Initiation of inotropes/vasopressor was either on the same day, one day later or two days later from time of prescription. 97% of the time, the agents were initiated on the same day they were prescribed as shown on figure 9 below.

**Figure 9: Time of inotrope initiation from time of prescription**
Through the study period patients were either on single or double inotropes. None of the 70 patients recruited were on three inotropes at any time. Dopamine was top as first inotrope while norepinephrine was top as being initiated as the second inotrope. This is depicted on figure 10 and 11 below.

**Figure 10: first inotrope of choice**

![Graph showing the percentage of patients receiving each inotrope as the first choice.](image)

**Figure 11: second inotrope of choice**

![Graph showing the percentage of patients receiving each inotrope as the second choice.](image)
When inotropes are prescribed the clinician is meant to set and document a target mean arterial pressure. Figure 12 below shows the distribution.

**Figure 12: Mean arterial pressure set target**

![Mean arterial Pressure](image)

For inotropes/vasopressors to be weaned off the patient must achieved the set target mean arterial pressure.

**Figure 13: achievement of target**

![Achievement of Target](image)
Mode of monitoring patients was grouped into either basic or advanced. In this study basic monitoring included ECG, non-invasive BP, heart rate and central venous pressure. Advanced monitoring included invasive BP and central venous oxygen concentration. Basic monitoring was most used.

**Figure 14: Mode of monitoring treatment**

![Mode of Monitoring Treatment](image)

To administer the inotropes infusion pumps were used 100% of the time.
DISCUSSION

Inotropes and vasopressors are lifesaving agents used on the critically ill patients who present with hypotension that is unresponsive to fluid resuscitation. At Kenyatta National Hospital the critically ill patients are taken care off in the main critical care unit, emergency ward in casualty and high dependency units. There were a total of 70 patients recruited in the study. Majority were female patients. Age distribution was from as young as month old to as old as 75yr, this is because there is currently no separate paediatric critical care unit.

Through the study period the inotropes/vasopressors used were: norepinephrine, dopamine, dobutamine and epinephrine. These are the agents that are currently present in the pharmacy drug formulary. There is a wider range of inotropes that could be used though not available at the hospital. Drugs such as vasopressin and phenylephrine would be useful additions. Vasopressin is useful in septic shock that is resistant to dopamine, norepinephrine and epinephrine (7). Phenylephrine is the drug of choice in neurogenic shock. Dopamine was the most used inotrope (41.4%) followed by norepinephrine (23.7%). This is comparable to a study on inotropes and vasopressors in Scandinavian intensive care units where dopamine was used most (47%) followed by norepinephrine (40%).(6)

The indication to start inotropes/vasopressors was in terms of type of shock diagnosed. Septic shock was the leading indicator to initiate inotrope therapy followed by cardiogenic shock and lastly neurogenic shock. This is possibly due to the fact that at KNH the CCU admits all types of patients as compared to other centres that have specialized ICUs. Though grouped into the different types of shock the patients had varied admitting diagnoses as shown on figure 6. In comparable studies main indications to initiate inotropes is hypotension and oliguria (16). In this study hypotension was 100% the reason for initiating inotropes/vasopressors.
Dopamine and norepinephrine were the inotropes of choice in patients with septic shock. This is in keeping with international guidelines (4). Norepinephrine was prescribed as the first inotrope in 51% of the patients with septic shock. In a comparative study between norepinephrine and dopamine, norepinephrine was found to be strongly related to favourable outcome though there was no significant difference in mortality rate (5, 6). Among the patients with septic shock double inotrope was at 48.6%. Therefore, there is 50% chance of being on double inotropes when managing septic shock. In septic shock not responsive to dopamine and norepinephrine epinephrine is the alternative. In this study epinephrine was not used on patients with septic shock though it’s available. Vasopressin is to be used when septic shock is resistant to all the three inotropes though it is not available in KNH.

Cardiogenic shock was mainly experienced by patients post open heart surgery. Inotropes of choice among these patients were dobutamine, dopamine and epinephrine as shown on table 4. These results are comparable to a study in Germany among patients with low cardiac output syndrome (LCOS) epinephrine (41.8%) was found to be the commonest. Followed by dobutamine (30.9%) and phosphodiesterase (14.8%) (10).

In terms of number of inotropes used in the management of cardiogenic shock, single inotrope use was at 87% and double inotrope was 13%. In a French multicentre survey of patients post cardiac surgery single inotrope use was 64%, double inotrope 26% and three inotropes 6%. During the study period no patient was on three inotropes (9). This may be possible because patients undergo triage before open heart surgery at KNH and therefore have a better cardiac status therefore less need for inotropes post-operatively while the type of cardiac surgery among patients recruited in French study was emergency and interventional.
In the paediatric age group dopamine and norepinephrine were the inotropes that were chosen. According to international guidelines dopamine is the first line of inotrope in children with shock and hypotension.

Pre-treatment circulatory shock offers a guide in the management of patients in shock. Ideally a MAP <60mmHg warrants the initiation of inotropes. In this study 68.9% of patients were started on inotropes when MAP was between 40-60mmHg. The patients with a pre-treatment circulatory MAP of <40mmHg had septic shock while patient started o inotropes when MAP was 60-80mmHg had neurogenic shock. In the neurogenic patients inotropes are initiated at a higher MAP in order to maintain cerebral perfusion pressure. In the paediatric group the clinical features of shock were used to start inotropes as compared to adults where MAP was the guide to initiate inotropes.

Prior to initiation of inotropes/vasopressor therapy fluid resuscitation is recommended. 55.7% of patients were resuscitated. Most of who had septic shock. Crystalloids were used mostly in resuscitation.

In assessing delay in initiation of inotropes it was found that 97% of the patients received treatment on the same day it was prescribed. Though initiated on the same day it wasn’t possible to ascertain the exact point the inotrope was initiated. This is important as there is a difference in initiating treatment immediately versus hours later though within the same day. Only 2 patients had delay in treatment initiation that may have been attributed to poor documentation of instructions.

On prescribing inotropes/vasopressors the clinician is meant to clearly document the target MAP. Target was documented in only 74% of the cases.
Achieving the set target MAP meant that the patient was weaned off inotropic support. This was achieved in 41% of the patients. Patients in whom target wasn’t achieved succumbed in the course of the study. The cause of mortality wasn’t in the scope of this study as other factors may have contributed to mortality and the duration of the study was limited.

Mode of monitoring treatment was either basic or advanced. As per this study basic monitoring included non-invasive BP, heart rate, central venous pressure. Advanced monitoring included invasive BP and central venous oxygen saturation. Basic monitoring is the minimally acceptable modes of monitoring to ensure safety and adequacy of monitoring. 69% of patients were on basic monitoring while 31% were on advanced monitoring. This is acceptable as all the patients were adequately monitored.

Infusion pumps were used to administer inotropes/vasopressors to all the patients. This is the acceptable international standard of administering inotropes. During the study it was observed that quick change was the method of choice in substituting infusion of inotropes. It is associated with a drop in BP while changing the syringes though it is cost-effective compared to double pumping (20).
CONCLUSIONS

1. Dopamine is the most used inotrope at Kenyatta National Hospital.

2. 97% of the time inotropes were initiated on time; on the same day they are prescribed.

3. Commonest indication for inotropes is septic shock.

4. There is adequate monitoring of patients on inotropic therapy.

5. There is proper administration of inotropes by use of infusion pumps.
RECOMMENDATIONS

1. Creation of an inotrope chart that will aid in proper documentation as the treatment is ongoing.

2. A larger study over a longer period to assess other factors such as complications and outcome of patients on inotropes.

3. Development of guidelines on inotrope use to aid in management of patients.

4. Expand pharmacy formulary to include other inotropes/vasopressors.
Appendix 1

Consent for participation

Consent explanation.

My name is Dr. Simiyu Victoria M., a postgraduate student in Anaesthesia at the University of Nairobi. As part of my course work I am required to perform clinical research. I am conducting a study at the Kenyatta National Hospital on the use of inotropes and vasopressor in KNH CCU, HDU and Emergency ward. These drugs are used to correct low blood pressure and also enhance the pumping of the heart. The aim of this study is to help doctors improve the care given to patients. To do this, I will review the notes on your relatives file and observe on-going treatment. Thereafter I will do statistical calculations on this information and publish it in a book that will be in the custody of the University of Nairobi. All information gathered will be treated with utmost confidentiality. No names or other identifiers will be used in the study. As a consequence I shall need your consent for your relative to be included in the study. There are no risks involved in participating in this study. The benefits are that management will be optimized should a shortcoming be encountered. Their participation in this study is voluntary and you may withdraw your relative at any point without affecting the treatment being given to them in any way. Any information obtained in the course of the study is beneficial in the management of the patient.

For further information and clarification you may contact:

Dr. Simiyu Victoria M. Telephone number – 0721396190
Dr. Murithi/Dr. Nabulindo – supervisors. Telephone number – 0722850375/0721418587
KNH/UON – Ethics & Research Committee. Prof. A.N. Guantai, Chair, Telephone number – 2726300 Ext. 44102
Statement by the researcher:

I confirm that the participant/next of kin was given an opportunity to ask questions about the study, and all the questions asked by the participants have been answered. I confirm the individual has not been coerced to participate in the study and the consent has been given freely and voluntarily.

Name:___________________________

Signature:________________________

Date:____________________________
**Consent Form**

I _________________ have been explained the purpose and conditions of my relative’s involvement in the study by Dr. Simiyu Victoria M. I agree to the above and do give consent for _________________ to be included in the study who is my relative, by virtue of being a………………..

Name: ___________________  Witness Name: ___________________

Signature: ___________________  Signature: ___________________

Thumb print: _________________  Thumb print: _________________

Date: ______________________  Date: ______________________

**Consent Form for patients who consent themselves**

I _________________ have been explained the purpose and conditions of my involvement in the study by Dr. Simiyu Victoria M. I agree to the above and do give consent to be included in the study.

Name: ___________________  Witness Name: ___________________

Signature: ___________________  Signature: ___________________

Thumb print: _________________  Thumb print: _________________

Date: ______________________  Date: ______________________
Idhini ya kushiriki katika utafiti

Maelezo.


Ushiriki wakuwa katika utafiti huu ni kwa hiari yako na unaweza kuondoa mwenzako (au tegemezi) katika hatua yoyote bila kuathiri matibabu atakayopewa mwenzako (au tegemezi) kwa njia yeyote. Taarifa zote zitakazopatikana katika mwendo wa utafiti huu ni manufaa kwa mgonjwa.

Kwa maelezo zaidi na ufanuzi, unaweza kuwasiliana na:

Daktari Simiyu Victoria M. Nambari ya simu – 0721396190
Dr. Murithi/Dr. Nabulindo Nambari ya simu – 0722850375/0721418587

KNH/UON – Ethics & Research Committee. Pof. A.N. Guantai, Mwenyekiti, Nambari ya simu – 2726300 Ext. 44102
**Idhini**

Mimi _________________ nimeelezewa madhumuni na masharti ya ushiriki wa mwenzangu (au tegemezi) katika utafiti na Daktari Simiyu Victoria M. Nakubaliana na maelezo hayo na nimemruhusu daktari kufanya utafiti huo kwa mwenzangu ________________.

| Jina: ______________________ | Jina la mshahidi: ______________ |
| Sahihi: ________________ | Sahihi: ______________________ |
| Finyo kidole cha gumba: ______ | Finyo kidole cha gumba: ___________ |
| Tarehe: ______________________ | Tarehe: ______________________ |

**Idhini**

Mimi _________________ nimeelezewa madhumuni na masharti ya ushiriki wangu katika utafiti na Daktari Simiyu Victoria M. Nakubaliana na maelezo hayo na nimemruhusu daktari kufanya utafiti huo kwangu.

| Jina: ______________________ | Jina la mshahidi: ______________ |
| Sahihi: ________________ | Sahihi: ______________________ |
| Finyo kidole cha gumba: ______ | Finyo kidole cha gumba: ___________ |
| Tarehe: ______________________ | Tarehe: ______________________ |
Appendix 2

QUESTIONNAIRE

BIODATA

Age:.......................  Sex:  M  F

Diagnosis:........................................................

1. Indication for inotrope/vasopressor agent
   - Septic shock
   - Cardiogenic shock
   - Anaphylactic shock
   - Neurogenic shock

2. Underlying condition:...........................................

3. Pre-treatment circulatory state-MAP(mmHg)
   - 60-80
   - 40-60
   - \( \leq 40 \)

4. Was the patient fluid resuscitated
   - yes
   - no

5. If yes No.4, what was used and what amount?
6. First choice of inotrope/vasopressor agent

<table>
<thead>
<tr>
<th>DRUG</th>
<th>DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• dobutamine</td>
<td></td>
</tr>
<tr>
<td>• dopamine</td>
<td></td>
</tr>
<tr>
<td>• epinephrine</td>
<td></td>
</tr>
<tr>
<td>• isopreterenol</td>
<td></td>
</tr>
<tr>
<td>• norepinephrine</td>
<td></td>
</tr>
<tr>
<td>• phenylephrine</td>
<td></td>
</tr>
<tr>
<td>• Vasopressin</td>
<td></td>
</tr>
</tbody>
</table>

7. Day of inotrope/vasopressor initiation

<table>
<thead>
<tr>
<th>Date of admission</th>
<th>Date of diagnosis requiring inotrope</th>
<th>Date of inotrope initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8. Did clinician set target mean arterial pressure:
9. Was a second inotrope/vasopressor needed:

- Yes
- No

10. Second inotrope/vasopressor initiated

<table>
<thead>
<tr>
<th>DRUG</th>
<th>DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine</td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td></td>
</tr>
<tr>
<td>Phenylephrine</td>
<td></td>
</tr>
<tr>
<td>Vasopressin</td>
<td></td>
</tr>
</tbody>
</table>

11. Was a third inotrope/vasopressor needed:

- Yes
- No

If yes, which one:_________________________
12. Was the target achieved:
   
   o Yes
   o No

13. Mode monitoring treatment
   
   o Basic-ECG, NON-INVASIVE BP, HEART RATE, CENTRAL VENOUS PRESSURE
   o Advanced-INVASIVE BP, CENTRAL VENOUS OXYGEN CONCENTRATION

14. What mode of administration was used?
   
   o Infusion pump
   o Other.........................
Appendix 3: Approval Letter

UNIVERSITY OF NAIROBI
COLLEGE OF HEALTH SCIENCES
P.O. BOX 19676 Code 00202
Telegram: varsity
(254-020) 2762300 Ext 44355

Ref: KNH-ERC/A/172

Dr. Simiyu Victoria M
Dept. of Anaesthesia
School of Medicine
University of Nairobi

Dear Dr. Simiyu

Research proposal: A survey on the use of Vasopressor and inotropic agents over three
Months at the Kenyatta National Hospital (P32/01/2014)

This is to inform you that the KNH/UoN-Ethics & Research Committee (KNH/UoN-ERC) has reviewed
and approved your above proposal. The approval periods are 5th June 2014 to 4th June 2015.

This approval is subject to compliance with the following requirements:

a) Only approved documents (informed consents, study instruments, advertising materials etc) will be used.
b) All changes (amendments, deviations, violations etc) are submitted for review and approval by KNH/UoN
   ERC before implementation.
c) Death and life threatening problems and severe adverse events (SAEs) or unexpected adverse events
   whether related or unrelated to the study must be reported to the KNH/UoN ERC within 72 hours of
   notification.
d) Any changes, anticipated or otherwise that may increase the risks or affect safety or welfare of study
   participants and others or affect the integrity of the research must be reported to KNH/UoN ERC within 72
   hours.
e) Submission of a request for renewal of approval at least 60 days prior to expiry of the approval period.
   (Attach a comprehensive progress report to support the renewal).
f) Clearance for export of biological specimens must be obtained from KNH/UoN-Ethics & Research
   Committee for each batch of shipment.
g) Submission of an executive summary report within 90 days upon completion of the study
   This information will form part of the data base that will be consulted in future when processing related
   research studies so as to minimize chances of study duplication and/or plagiarism.

For more details consult the KNH/UoN ERC website www.uonbi.ac.ke/activities/KNHUoN.
Yours sincerely

PROF. M. L. CHINDIA
SECRETARY, KNH/UoN-ERC

C.C. The Principal, College of Health Sciences, UoN
      The Deputy Director CS, KNH
      The Chairperson, KNH/UoN-ERC
      The Assistant Director, Health Information, KNH
      The Dean, School of Medicine, UoN
      The Chairman, Dept. of Anaesthesia, UoN
      Supervisors: Dr. J.M. Murithi, Dr. S. Nabulindo
REFERENCES


3. Nalaka G., Scott M.- Physiology and principles of the use of vasopressors and inotropes.


7. Role of vasopressin in the management of septic shock.
Mutlu GM, Factor P. Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine.


16. Department of Anaesthesiology & Intensive Care, Karolinska Hospital, Stockholm, Sweden.

18. Clinical practice parameters for haemodynamic support of paediatric and neonatal septic shock; 2007 update from American College of Critical Care Medicine

19. Quick change versus double pump while changing the infusion of inotropes: an experimental study. de Barbieri I, Frigo AC, Zampieron A.
